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Targeting Hsp27/eIF4E interaction with phenazine compound: 
a promising alternative for castration-resistant prostate cancer 
treatment
SUPPLEMENTARY MATERIALS
Bioluminescence resonance energy transfer 
(BRET) assay
Construction of BRET plasmids
Hsp27 or eIF4E genes alone or with kozak sequence 
upstream were first inserted into the pCR8/GW/TOPO 
plasmid (Invitrogen). Kozak sequence was added each 
time the gene was found in N-ter in the final plasmid. 
For the insertion into pCR8/GW/TOPO plasmid, genes 
were first amplified by PCR using Phusion enzyme 
(Finnzymes, Thermo Fisher Scientific, Illkirch, France) 
and the following BRET primers: Hsp27: Forward=5’-
ATG ACC GAG CGC CGC GTC CC-3’, Forwardkozak= 
5’-GCC ACC ATG ACC GAG CGC CGC GTC CC-3’, 
Reverse=5’-CTT GGC GGC AGT CTC ATC GG-3’, 
eIF4E: Forward=5’-ATG GCG ACT GTC GAA CCG 
GAA AC-3’, Forwardkozak=5’- GCC ACC ATG GCG ACT 
GTC GAA CCG GAA AC-3’, Reverse=5’-AAC AAC 
AAA CCT ATT TTT AGT GGT GG-3’. Then, dATP with 
Go Taq enzyme (Promega, Charbonnieres, France) were 
added at the ends of the gene (PCR product) to allow 
matching between gene and plasmid. Genes were then 
purified from the PCR product with the Wizard SV Gel 
and PCR Clean-Up System kit (Promega). The insertions 
into plasmids were realized by TOPO reaction according 
to manufacturer’s instructions (Invitrogen). Competent 
bacteria “MACH 1” (Invitrogen) were transformed using 
TOPO reaction products and the clones we obtained 
were analysed by PCR with Go Taq enzyme (Promega). 
Positives clones were amplified by mini-culture and 
DNA was extracted with Wizard Plus SV Minipreps 
DNA Purification System kit (Promega), and sent for 
sequencing (M13 Forward primer) (GATC, Mulhouse, 
France). The second step was gene transfer from 
pCR8/GW/TOPO intermediate plasmids to destination 
plasmids containing luciferase and YFP by LR Gateway 
recombination reaction using LR clonase according to 
manufacturer’s instructions (Invitrogen). The destination 
plasmids pRLuc-C, pRLuc-N, pEYFP-N and pEYFP-C 
were received from Nelson Dusetti (UMR 1068, Centre 
Recherche Cancérologie Marseille, France). Competent 
bacteria “MACH 1” (Invitrogen) were transformed 
using LR reaction products. The clones obtained were 
amplified by mini-culture and DNA was extracted with 
the Wizard Plus SV Minipreps DNA Purification System 
kit (Promega). Enzymatic digestion by BsrGI (Promega) 
was performed in order to identify positives clones that 
were then amplified by maxi-culture and DNA was 
extracted using the PureYield Plasmid Midiprep System 
kit (Promega), and sent for sequencing (BRET primers) 
(GATC). For each gene (Hsp27, eIF4E) four plasmids with 
luciferase or YFP in N-terminal or C-terminal part were 
constructed. Constructs were checked by western blot, 
fluorescence visualization, and luminescence reading.
BRET in living cells
HEK293T cells cultured in 12-well culture plates 
(400 000 cells/well) were co-transfected with 0.2 μg 
of BRET donor plasmid 
N-ter
luc/eIF4E, and 0 to 1 μg 
of BRET acceptor plasmid Hsp27/YFP
C-ter
. The empty 
vector (pEYFP-C) was used to equalize DNA amounts 
to 1.2 μg in each sample. After 24h, cells were harvested 
and distributed in 96-well white microplates (≈40 000 
cells/well). On the following day, the cell-permeable 
Rluc substrate coelenterazine-h (Interchim, Montluçon, 
France) diluted in phosphate buffered saline (PBS) 1X 
was added in culture medium to a final concentration of 
5 μM, and cells were incubated 15 min at 37°C before 
reading. Readings were done using a LB 941 Tristar 
reader (Berthold France SA, Thoiry, France), with signal 
detection in the 470-490 nm (donor) and 520-540 nm 
(acceptor). BRET signal represents the BRET ratio of the 
Rluc and EYFP expression constructs compared to the 
BRET ratio for the Rluc expression construct alone. To 
assess signal variation, the BRET values were determined 
by using the following equation, expressed in milli-BRET 
unit (mBretU):
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where E
0
 corresponds to the ratio 530 nm acceptor 
signal/480 nm donor signal obtained with the Rluc 
construct alone in the same experiment. All experiments 
were performed at least three times with comparable 
results.
BRET in cell extracts
HEK293T cells were transfected separately with 
a BRET donor plasmid 
N-ter
luc/eIF4E or BRET acceptor 
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plasmid Hsp27/YFP
C-ter
. After 48h, total cellular proteins 
were extracted following manufacturer’s instructions of 
CelLytic NuCLEAR Extraction Kit (Sigma-Aldrich) and 
stored at -80°C. 1 μg of lysate containing a BRET donor 
N-ter
luc/eIF4E (or 4μg for CCND3/luc) was mixed with 0 to 
30 μg of lysate containing a BRET acceptor Hsp27/YFP
C-
ter (or CDK6/YFP) and with lysis buffer in a 96-well white 
plate. After 30 min of incubation at RT, coelenterazine-h 
(Interchim) was added to a final concentration of 5 μM in 
lysis buffer, just before reading. For chemical compounds 
screening, cellular extracts containing BRET donor or 
acceptor were pre-incubated separately during 2 hours 
at 4°C with 0, 20, 50 and 100 μM of each compound, 
and then mixed as indicated above. Cell extracts were 
incubated with 1% DMSO alone for control.
Compound 14 is not a DNA intercalating agent 
(Ethidium bromide exclusion assay)
5μg of DNA (Calf-Thymus DNA, Sigma-Aldrich, 
St Louis, Mo, USA) and 1μg of Ethidium Bromide at 
0.1mg/ml (EtBr, Sigma-Aldrich, St Louis, Mo, USA) 
were mixed together in milliQ water to obtain a volume 
of 50μl per well, in a black 96 well plate. The mixture 
was incubated for 15 min at room temperature (RT), 
protected from light, to allow the formation of the DNA/
EtBr complex. Compound 14 and control compounds 
were diluted in milliQ water at different concentrations 
(25, 50, 100, 200μM) and added to the mixture to achieve 
the desired concentration (total volume = 100μl). After 
1 hour incubation at RT in the dark, the DNA/EtBr 
complex was excited at 560nm and the fluorescence 
emission was recorded at 590 nm by using an OD reader 
(Fluostar Optima, Bmg Labtech, Ortenberg, Germany). 
Fluorescence values were normalized to wells containing 
only CT-DNA and EtBr. Doxorubicin (Teva classics, 
Pharmachemie b.v., Haarlem, Pays-Bas) was used as a 
positive control, while Docetaxel (Sanofi, Paris, France) 
and Gemzar (Lilly, Neuilly-sur-Seine, France) were 
employed as negative controls. Fluorescence of each 
compound alone was also tested at 200μM for the presence 
of background noise. Experiments were performed in 
triplicate.
After the promising results of compound 14 on the 
Hsp27/eIFE4 interaction, we performed a DNA binding 
assay to confirm that this compound was not a DNA 
intercalating agent potentially acting on DNA synthesis. 
We measured the fluorescence of DNA/Ethidium Bromide 
(BET) complex with and without our compound. We 
used Docetaxel and Gemzar as negative controls and 
Doxorubicin as a positive control, respectively. As 
represented in Supplementary Figure 1, we observed 
that phenazine compound 14 did not show any inhibition 
of the fluorescence of DNA/BET complex at all tested 
concentrations. In the contrary, Doxorubicin removed 
BET from DNA, thereby decreasing fluorescence. In 
parallel, the auto-fluorescence of the compound was 
tested at the highest dose, and no interference with the 
assay was detected. Our results allowed us to conclude 
that compound 14 was not a DNA intercalating agent.
Hsp27 mutant plasmids
Hsp27 deletion mutant plasmids (pcDNA4-
His-Hsp27 WT, -Hsp27 N1, -Hsp27 N2, -Hsp27 
C1, -Hsp27 C2) were a gift from Edward O’Brien 
(University of Ottawa Heart Institute, Canada) [27]. 
Hsp27 phosphorylation mutant plasmids (pENTR-Hsp27 
WT, -Hsp27 3A, -Hsp27 3D) were donated by William 
Gerthoffer (University of Nevada School of Medicine, 
USA) [27]. LR gateway recombination reactions were 
performed between pENTR and pDEST26 (Invitrogen) 
destination plasmids, according to manufacturer’s 
instructions (Invitrogen). All plasmids contained a 
histidine tag, merged to the proteins when produced, 
allowing the differentiation between endogenous and 
transfected proteins.
Chemical compounds
Phenazine derivatives were obtained from Michel 
Camplo and Olivier Siri (CINaM, Marseille, France) 
and resuspended in DMSO. Docetaxel was obtained 
from Sanofi-aventis (Paris, France) and stock solution 
of docetaxel was prepared with DMSO to the required 
concentrations before each experiment.
Treatment of cells with chemical compounds
PC-3 and PC DR cells were seeded into 10-cm dishes 
(1 250 000cells/well) or 12-well plates (50 000 to 100 
000cells/well) according to the different experiments. 
One day after seeding, medium was changed to a new one 
containing DMSO (control) or compound 14 at different 
concentrations (25, 50, 100μM), according to the different 
experiments. Effects of the treatment were analyzed 48h 
later. The REG cells were transiently transfected with 
Hsp27 deletion mutant plasmids for 48h and treated after 
this with docetaxel (1nM) and the same protocol was 
used for transfection of Hsp27 phosphorylation mutant 
plasmids, treated with docetaxel (10 nM) in serum-free 
media (mimics androgen withdrawal in vitro).
Molecular modeling studies
Compound 14 was parameterized according to a 
consolidated procedure [1-4]. The unavailable 3D model 
structure of the full length wild-type (WT) Hsp27 was 
built and optimized by homology modeling/refining 
techniques [5]. The models of the three Hsp27 truncated 
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variants were obtained by deleting the relevant amino acid 
sequences, and optimizing the corresponding isoforms 
via energy relaxation/MD simulations in solution. The 
same protocol was employed to optimize the available 3D 
model of eIF4E (5BXV.pdb).
The docking modes of eIF4E onto WT Hsp27 and its 
three truncated isoforms were determined and optimized 
as described in our previous work [6, 7]. The relaxed 
Hsp27/eIF4E complexes were subjected to full-solvation 
molecular dynamics (MD) simulations, exploiting the last 
100 ns of the MD data collection for the calculation of the 
binding free energy between the two proteins via the MM/
PBSA (Molecular Mechanics/Poisson Boltzmann Surface 
Area) approach [8].
To study the mechanism of interference exerted on 
eIF4E/Hsp27 binding, compound 14 was docked into the 
eIF4E binding pocket, and the MM/PBSA scoring was 
again applied to estimate the affinity of 14 for eIF4E.
Finally, the ternary complex Hsp27/14/eIF4E was 
built by docking the MD Hsp27 model onto the last frame 
of the eIF4E/14 complex extracted from the corresponding 
equilibrated MD trajectory. The whole computational 
procedure was then applied again to study the binding 
energetics of the protein/drug/protein ensemble (see SI 
for full details). All simulations were carried out using the 
Pmemd modules of Amber 14 [9], running on a hybrid 
CPU/GPU calculation cluster.
Optimization of compound 14
The Amber ff14SB force field (Maier et al 2015) 
was used to parametrize all protein structures. The atomic 
partial charges for 14 were obtained using the RESP 
procedure (Bayly et al 1993), the electrostatic potentials 
being produced by single-point quantum mechanical 
calculations at the Hartree- Fock level with a 6-31G* 
basis set, using the Merz-Singh-Kollman van der Waals 
parameters (Besler et al 1990). Eventual missing force 
field parameters for the inhibitor molecule were generated 
using the Antechamber tool of Amber 14 (Case et al 2014) 
and the general AMBER force field (GAFF) (Wang et al 
2010) for rational drug design.
Building and refinement of Hsp27/eIF4E 
complexes
The Hsp27/eIF4E protein-protein interface and the 
docking modes of eIF4E onto WT Hsp27 and its three 
truncated isoforms were determined using the HADDOCK 
server [10]. The resulting protein/protein docked 
conformations were clustered and visualized; then, in the 
absence of any relevant crystallographic information, the 
structure of each complex characterized by the lowest 
interaction energy in the prevailing cluster was selected 
for further modeling [7]. The selected Hsp27/eIF4E 
complexes were then solvated in a TIP3P [11] water box 
and, then, the required amount of Na+ and Cl- ions were 
added to neutralize the system and to mimic physiological 
salt conditions (150 mM), removing eventual overlapping 
water molecules. The solvated systems were subjected 
to a combination of steepest descent/conjugate gradient 
minimization of the potential energy, during which all 
bad contacts were relieved. The relaxed systems were 
then gradually heated to 300 K in three intervals by 
running constant volume-constant temperature (NVT) 
MD simulation, allowing a 0.5 ns interval per 100 K. 
Subsequently, 40 ns MD simulations under isobaric-
isothermal (NPT) conditions were conducted to fully 
equilibrate each solvated compound. The SHAKE 
algorithm with a geometric tolerance of 5x10-4 Å was 
imposed on all covalent bonds involving hydrogen atoms. 
Temperature control was achieved using the Langevin 
temperature equilibration scheme and an integration time 
step of 2 fs. The particle mesh Ewald (PME) method [12]
was used to treat the long-range electrostatics. At this 
point, these MD runs were followed by other 200 ns of 
NVT MD simulation.
eIF4E purification
eIF4E was cloned into pT7, the proteins were 
expressed in Bl21 STAR strain in LB in the presence of 
100μg/mL ampicillin. Cultures were inoculated at 37 °C 
and grown to an OD
600
 of 0.9 at 37 °C, then induced with 
0.5 mM Isopropyl-β-D-thio-galactoside (IPTG) and grown 
overnight at 24°C. Cells were harvested by centrifugation, 
cell pellets were resuspended in buffer (hepes 50mM [pH 
7.6], 100 mM NaCl, 1mM EDTA, 1 mM dithiothreitol 
[DTT] and complete with protease Inhibitor Cocktail 
Tablets. Cells were lysed by a Sonicate and the lysate 
was cleared by centrifugation at 1h, 13000rpm. During 
spinning, equilibrate ~2ml of m7GDP resin with the 
Elution wash buffer (Hepes 50mM (pH 7.5), KCl 2M, 
EDTA 1mM+DTT 1mM). The cleaved complexes were 
eluted with the same buffer. Concentrate to 1 ml and 
dialysis o/n into 50mM Phosphate pH 7.4, 50 mM NaCl, 
1mM DTT. Then, add 1ml of 50 mM Phosphate buffer 
to dilute salt to 25mM and pass through ion exchange 
(MonoQ; salt gradient from 25 mM to 1 M NaCl). The 
gel-filtered protein complex was further purified by ion 
exchange on Resource Q (GE Healthcare) with a gradient 
from 150 mM to 1M NaCl.
ITC studies on the binding of eIF4E/14 complex
Isothermal titration calorimetry (ITC) experiments 
were performed with a MicroCal PEAQ-ITC calorimeter 
(Malvern, UK) at 25°C (cell volume = 280 μL). 
Thermodynamics of eIF4E/14 complex formation was 
investigated in HEPES buffered solutions at pH=7. 
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Specifically, a solution of eIF4E (25μM, sample cell) was 
titrated with 19 step-by-step injections of 2μL volume of 
14 (250 μM, syringe). Solutions and buffer were degassed 
for 30 min at room temperature under stirring at 750 rpm 
prior to each experiment.
Molecular mechanics/poisson-boltzmann (MM/
PBSA) theory
According to the MM/PBSA theory, the free energy 
of binding (Δ G
bind
) between eIF4E and each Hsp27 
variant can be calculated as the sum of different energetic 
contributions, corresponding to the average MD energies 
(ΔE
MM
 = ΔEele + ΔEvdW), the average solvation free 
energy (ΔG
solv
 = ΔG
solv,pol
 + ΔG
solv,nonpol
), and the entropic 
contribution (−TΔS). To further estimate the relative 
contribution of the residues involved in the protein/
protein binding interface to the overall binding event, the 
enthalpic term of the ΔG
bind
 was deconvoluted into its main 
components for each individual residues (ΔH
bind,res
) of the 
proteins in the corresponding systems. This analysis was 
carried out using the MM/GBSA approach, [13, 14] and 
was based on the same snapshots considered for binding 
free energy calculation.
Protein-protein free energy of binding
To study the mechanism of interference exerted 
on eIF4E/Hsp27 binding, the optimized structure of 
compound 14 was initially docked into the retrieved eIF4E 
binding pocket by exploiting Autodock 4.3/Autodock 
Tools 1.4.6 (Morris et al 2009). The same cluster analysis, 
complex optimization, MM/PBSA and MM/GBSA scoring 
recipes described above for the eIF4E/Hsp27 ensemble 
was the applied to estimate the affinity of 14 for eIF4E.
Interference of compound 14 with the Hsp27/
eIF4E complex formation
Finally, the ternary complex Hsp27/14/eIF4E was 
built by docking the MD Hsp27 model onto the last frame 
of the eIF4E/14 complex extracted from the corresponding 
equilibrated MD trajectory. The whole computational 
procedure was then applied again to study the binding 
energetics of the protein/drug/protein ensemble.
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Supplementary Figure 1: Compound 14 is not a DNA intercalating agent. (a) 5μg of DNA and 1μg of Ethidium Bromide at 
0.1mg/ml were mixed together in water and incubated for 15 min at RT to allow the formation of the DNA/EtBr complex. Compound 14 
and control compounds were diluted in milliQ water at different concentrations (25, 50, 100, 200μM) and added to the mix to achieve 
the desired concentration and. After 1hour incubation at RT, the DNA/EtBr complex was excited at 560nm and the fluorescence emission 
was recorded at 590 nm by using an OD reader. The fluorescence values were normalized to wells containing only DNA and EtBr. (b) 
Fluorescence of each compound alone, measured by optic density (OD), has also been tested at 200μM to test the presence of a background 
noise that can disturb the analysis.
